Cure8 news brief
A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It also signals competition and potential label-expansion activity in IBD treatments.
Adults with Crohn’s disease, patients on or considering biologic therapy, clinicians treating IBD, researchers following IBD drug development, and patient advocates tracking treatment access and pricing.
AbbVie presented Phase 3 AFFIRM results showing subcutaneous SKYRIZI (risankizumab) induced endoscopic remission and ulcer-free endoscopy in a meaningful share of adults with moderately to severely active Crohn’s disease, with a safety profile consistent with prior data. The Yahoo!
Finance piece summarizes these clinical findings and discusses their potential financial and strategic implications for AbbVie, including competition with Rinvoq (upadacitinib) and broader pressures from drug-pricing policy.
The article is an investor-oriented analysis rather than a clinical report; it highlights the possible regulatory pathway for a subcutaneous SKYRIZI induction option and frames the data as supportive of AbbVie’s immunology growth narrative.
It does not provide detailed efficacy numbers, patient eligibility criteria, or safety event rates — those would be in the original AFFIRM presentations or primary study reports.
If you want clinical details (response and remission rates, safety events, or regulator timelines), look for the AFFIRM poster/abstract from the 2026 ACG meeting or AbbVie’s formal press release and FDA/EMA filings.
This article is an investment-focused summary of AFFIRM Phase 3 data presented at the 2026 ACG meeting; it does not present full trial data or regulatory decisions. For clinical decision-making, consult the primary trial report, conference abstract, or regulatory communications.
The piece also discusses company-level financial projections and drug-pricing risks which are outside direct clinical implications.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
